- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02019381
Study the Effects of Vitamin D and Calcium Supplementation at Tolerable Upper Limit Doses on Calcium Metabolism.
The Effects of Vitamin D and Calcium Supplementation at Tolerable Upper Limit Doses on Calcium Metabolism in Postmenopausal White Women.
Study Overview
Status
Conditions
Detailed Description
The specific aims of this study proposal are to determine the following:
- To compare the two different intake guidelines for Calcium and Vitamin D Supplementation at its recommended tolerable upper limit on serum and urinary calcium in white postmenopausal Women.
- Compare the effects above mentioned two intake guidelines on Vitamin D metabolism [25(OH)D, 1,25(OH)2D] and bone turnover.
Participants will be randomly assigned to Group A or Group B based on different dosages of study medications.
Group A: 10,000 IU (International Units)Vitamin D + Placebo (sugar pill) 600IU Vitamin D + Two pills Calcium containing 600mg calcium each.
Group B: 600 IU Vitamin D + Placebo (sugar pill) 10,000 IU Vitamin D
+ Two pills Calcium containing 600mg calcium each.
In addition to the calcium supplements, they will guide to include approximately 800mg of calcium in their daily diet.
At visit 2, fasting blood and spot urine will be collected. A urinal will be dispensed for collection of 24-hour urine for urinary calcium to be brought in next day. Study medication will be dispensed and participants will be asked not to discard unused medications and to bring all study medications next study visit.
Visit 3, 4, 5, 6 will essentially be the same as visit 2, with subjects returning unused study medication and given new tablets each visit. Except on visit 6 no further study medications will be dispensed, after collecting the previous supply.
Food frequency questionnaires will be filled out at the initial visit and final visit. Diet will be assessed using 3-day diet history form and Nutrition Pro analysis software. Patients will be asked to refrain from taking other Vitamin D supplements and to continue their usual calcium intake.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
New York
-
Mineola, New York, United States, 11501
- Winthrop University Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Healthy White women aged 50 and older who have been postmenopausal for at least 2 year (i.e. absence of menstrual period for a period of 24 months or more).
- Willingness to discontinue self-administration of vitamin D and calcium supplements. Participants must be at least three months off supplements before starting the study.
- Willingness to take study medications and participate in study for one year.
- Written informed Consent Signed.
- Patients with hypertension and diabetes stable for last three months.
Exclusion Criteria:
- History of hypercalciuria (24-hour urinary calcium excretion >250 mg), hypercalcemia (serum calcium >10.6), nephrolithiasis and active sarcoidosis will be excluded.
- Serum 25-hydroxyvitamin D level >80 nmol/L or history of primary hyperparathyroidism.
- Dietary calcium intake of >2000mg/day will be excluded
- Use of medication that influences bone or vitamin D metabolism (e.g. anticonvulsant medications, glucocorticoids, Highly Active AntiRetroviral Therapy [AIDS treatment], antirejection medications, chronic use of steroids, high dose diuretics)
- Treatment with Hormone replacement therapy, Selective Estrogen Receptor Modulators, Calcitonin, Parathyroid hormone , androgens, bisphosphonates, phosphate or anabolic steroids 6 months prior to the study.
- Use of systemic steroids (oral or intravenous) within the last year at an average dose of more than 5mg/day of oral prednisone or an equivalent for a period of three months or more prior to screening.
- Chronic medical illness including Chronic liver disease, uncontrolled diabetes mellitus; recent history of myocardial infarction or heart failure; newly diagnosed or active malignancy; uncontrolled hypertension; obesity (BMI>35 kg/m2); malabsorption, anemia, leukemia, or other hematologic abnormalities; lupus, rheumatoid arthritis, sarcoidosis, or other rheumatologic disease; chronic kidney disease, metabolic bone disease.
- Unexplained weight loss of >15% during the previous year or history of anorexia nervosa
- > 1 pack per day tobacco use or > 2 alcoholic beverages per day
- Unwillingness to forego self-administration of vitamin D and calcium-containing supplements.
- Participation in another investigational trial in the past 30 days prior to the screening evaluation
- Significant deviation from normal in medical history, physical examination, or laboratory tests as evaluated by the primary investigator.
- Patients with unstable hypertension or diabetes.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Health Services Research
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Other: Endocrine Society UL Dosage Vitamin D
Participants will be randomly assigned vitamin D + calcium dose based on Endocrine Society Upper limit guidelines.
And given 10,000IU Vitamin D + 1200mg Calcium (600IU Placebo Vitamin D, in addition to two calcium tablets of 600mg) each to be taken per day.
|
Endocrine Upper limit arm will get 10,000IU Vitamin D and 1200mg Calcium
1200mg of CaCO3 supplementation will be given to each participant in both groups
|
Other: Institute of Medicine Dosage Vitamin D
Participants will be randomly assigned Vitamin D dose based on IOM guidelines; calcium dose will be as per IOM upper limits.
And will receive 600 IU Vitamin D + 1,200 mg of calcium tablets to be taken per day.
|
1200mg of CaCO3 supplementation will be given to each participant in both groups
IOM arm will get 600 IU Vitamin D and 1,200 mg Calcium
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Compare the effects of 10000 IU/day vitamin D plus 2,000 mg/day calcium versus 600 IU/day vitamin D plus 2,000 mg/day calcium on incidence of hypercalciuria (spot urine calcium:creatinine ratio, 24-hour urine calcium).
Time Frame: One year
|
Endocrine society has recommended tolerable upper limit or a dose with no adverse events as 10,000IU of Vitamin D and 2000 mg/day of calcium.
Our study will test the safety/ efficacy of this recommendation.
|
One year
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Compare the effects of 10,000 IU/day vitamin D plus 2,000 mg/day calcium versus 600 IU/day vitamin D plus 2,000 mg/day calcium on vitamin D metabolism [25(OH)D, 1,25(OH)2D], and bone turnover.
Time Frame: One year
|
To test safety/efficacy of The Endocrine Society recommendations on Bone turnover.
|
One year
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: John Aloia, MD, Winthrop UH
- Study Director: Mageda Mikhail, MD, Winthrop UH
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 13005
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Delusion of Reference
-
Instituto de Cardiología y Medicina Vascular Hospital...CompletedReference Values of BNP in Healthy Newborn
-
Setint AI Robotic Sistem Egitim ve Danısmanlık...RecruitingPredictive Value of Tests | Vital Signs | Reference Values | Laboratory Critical Values | Relative Value ScalesTurkey
-
Mental Health Services in the Capital Region, DenmarkCentral Denmark Region; Mental Health Services in the North Denmark RegionActive, not recruitingPsychotic Disorders | Schizophrenia and Related Disorders | Schizotypal Disorder | Schizophrenia Prodromal | Paranoid Schizophrenia | Paranoid Ideation | Paranoid Delusion | Ideas of Reference | Psychosis Paranoid | Psychotic Paranoia | Psychotic; Disorder, DelusionalDenmark
-
Miguel Ayala LeónNational Institute of Medical Sciences and Nutrition, Salvador ZubiranUnknownReference Values | Echocardiography, StressMexico
-
Oslo University HospitalCompletedReference ValuesNorway
-
Johann Wolfgang Goethe University HospitalCompleted
-
Chinese Academy of Medical Sciences, Fuwai HospitalRecruitingHealthy Participants | Reference ValuesChina
-
The Hospital for Sick ChildrenMINDRAYCompletedEstablish Hematology Reference IntervalsCanada
-
USDA, Western Human Nutrition Research CenterUniversity of Copenhagen; Bill and Melinda Gates Foundation; International Centre... and other collaboratorsRecruitingHuman Milk Nutrient Reference ValuesDenmark, Bangladesh, Brazil, Gambia
-
Children's Hospital Medical Center, CincinnatiEunice Kennedy Shriver National Institute of Child Health and Human Development... and other collaboratorsCompleted
Clinical Trials on Endocrine Society UL Dosage Vitamin D
-
Azienda Ospedaliera Specializzata in Gastroenterologia...Unknown
-
Centre Hospitalier Departemental VendeeCompleted
-
Lo.Li.Pharma s.r.lCompleted
-
Saiful Anwar HospitalCompletedSystemic Lupus ErythematosusIndonesia
-
Children's Hospital of Fudan UniversityRecruitingCholangitis | Anti-Bacterial Agents | Biliary AtresiaChina
-
National Cancer Institute (NCI)RecruitingAnatomic Stage III Breast Cancer AJCC v8 | Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma | Anatomic Stage IV Breast Cancer AJCC v8 | Advanced Malignant Solid Neoplasm | Locally Advanced Malignant Solid Neoplasm | Unresectable Malignant Solid... and other conditionsUnited States, Puerto Rico